Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes
Open accessAbstract
Cancer Research UK T cell checkpoint-targeted immunotherapy is effective in multiple cancers, but only in subsets of patients [1.Topalian S.L. Hodi F.S. Brahmer J.R. et al.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med. 2012; 366: 2443-2454Crossref PubMed Scopus (9274) Google Scholar]. Failure of immunotherapy may be secondary to tumour intrinsic and/or systemic factors that impair immune response. Glucocorticoid administration has known systemic immunosuppressive effects [2.Wolfe F. Caplan L. Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.Arthritis Rheum. 2006; 54: 628-634Crossref PubMed Scopus (388) Google Scholar] with potential to impair immunotherapy outcome [3.Flint T.R. Janowitz T. Connell C.M. et al.Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity.Cell Metab. 2016; 24: 672-684Abstract Full Text Full Text PDF PubMed Scopus (190) Google Scholar], and should therefore be regulated at patient enrolment. We performed a cross-sectional analysis of T cell checkpoint-targeted cancer immunotherapy trials in solid malignancies registered on the U.S. National Institutes of Health (NIH) trial registry (clinicaltrials.gov) by October 7, 2016. Trials were searched by study type, condition, and interventions targeting the T cell checkpoint proteins CTLA-4, PD-1, PD-L1, PD-L2, LAG3, B7-H3, CD137, OX40, CD27 and GITR. Trials were reviewed manually and independently by two clinicians and registered data on glucocorticoid administration within enrolment criteria recorded. We identified 1017 registered T cell checkpoint-targeted cancer immunotherapy trials. The number of registrations has progressively increased, exponentially between 2010 and 2015 (R2 = 0.95) (Figure 1A). For the completed years, 2001–2015, chronic glucocorticoid administration was stated as an exclusion criterion in 40% (276/685), permitted in 29% (201/685) and not specified in 30% (208/685) of trial registration details. The proportion of trials that did not allow glucocorticoid use has decreased significantly (P < 0.001), while the proportion allowing glucocorticoid use has increased significantly (P < 0.001) (Figure 1B). Of the trials permitting glucocorticoid use, the maximum permitted dose of prednisolone equivalent per day was up to 10 mg in 57% of trials (115/201), over 10 mg in 4% of trials (9/201) and not specified in 14% of trials (28/201); 24% of trials (49/201) permitted chronic glucocorticoid use for physiological replacement. These findings are concerning. The immunosuppressive effects of glucocorticoids are dose dependent, starting at less than 10 mg of prednisolone per day [2.Wolfe F. Caplan L. Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.Arthritis Rheum. 2006; 54: 628-634Crossref PubMed Scopus (388) Google Scholar], and may be compounded by hypoalbuminaemia present in patients with cancer [4.Lewis G. Jusko W. Burke C. Graves L. Prednisone side-effects and serum-protein levels.Lancet. 1971; 298: 778-781Abstract Scopus (165) Google Scholar]. Moreover, our pre-clinical work has demonstrated that low dose glucocorticoid administration is sufficient to suppress response to cancer immunotherapy [3.Flint T.R. Janowitz T. Connell C.M. et al.Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity.Cell Metab. 2016; 24: 672-684Abstract Full Text Full Text PDF PubMed Scopus (190) Google Scholar]. Therefore, unregulated glucocorticoid administration may result in treatment failure independent of the T cell checkpoint-targeted agent or tumour type. The use of glucocorticoids as appetite stimulants and anti-emetics, particularly relevant in combination trials with emetogenic chemotherapy or radiotherapy, may also be immunosuppressive and will require critical review. While the use of glucocorticoids for adrenal replacement or chronic immune illness may be unavoidable, stratification for their use at enrolment should be considered. In addition to glucocorticoid administration, endogenous glucocorticoid levels may also impact on response to immunotherapy. Monitoring and stratification according to baseline glucocorticoid levels, or clinical surrogates of these such as longitudinal weight measurements [3.Flint T.R. Janowitz T. Connell C.M. et al.Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity.Cell Metab. 2016; 24: 672-684Abstract Full Text Full Text PDF PubMed Scopus (190) Google Scholar], may yield predictive and prognostic markers of response. We note that the chronic use of glucocorticoids should be considered independently from the use of glucocorticoids in managing immune-related adverse events during immunotherapy. In fact,
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
It has been difficult to investigate the effect of GCs on CPI in patients with cancer due to confounding by performance status and comorbidities, inconsistent CPI trial inclusion criteria, and difficulties in performing well-controlled trials.
“This has remained difficult to investigate in patients with cancer due to confounding by performance status and comorbidities,32 inconsistent CPI trial inclusion criteria,29 and the difficulties in performing well-controlled trials in this context.”
From Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy (2023) · cites this paper as [29]
In vivo models of cancer suggest that even low doses of GCs can impair the efficacy of checkpoint immunotherapy and suppress anti-tumor immunity, leading to enhanced metastasis and reduced survival.
“However, in vivo models of cancer also suggests that even low doses of GCs can impair the efficacy of CPI29,30 and suppress anti-tumor immunity,30 leading to enhanced metastasis and reduced survival.31”
From Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy (2023) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624 · see citing works
Wolfe, F., Caplan, L., & Michaud, K. D. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21568 · Cited by 472 · see citing works
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity
Flint, T. R., Janowitz, T., Connell, C. M., Roberts, E. W., Denton, A. E., Coll, A. P., Jodrell, D. I., & Fearon, D. T. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.010 · Cited by 367 · see citing works
Self-citationTrial Reporting in ClinicalTrials.gov — The Final Rule
Zarin, D. A., Tse, T., Williams, R. J., & Carr, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmsr1611785 · Cited by 332 · see citing works
PREDNISONE SIDE-EFFECTS AND SERUM-PROTEIN LEVELS
Lewis, G., Jusko, W., Burke, C. W., & Graves, L. (1971) · The Lancet · doi:10.1016/s0140-6736(71)92738-3 · Cited by 240 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tumors induce de novo steroid biosynthesis in T cells to evade immunity
Mahata, B., Pramanik, J., van der Weyden, L., Polański, K., Kar, G., Riedel, A., Chen, X. X., Fonseca, N. A., Kundu, K., Campos, L. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17339-6 · Cited by 329 · see citing works
Fessas, P., Lee, H., Ikemizu, S., & Janowitz, T. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.002 · Cited by 258 · see citing works
Self-citationAdrenocortical carcinoma — towards genomics guided clinical care
Crona, J., & Beuschlein, F. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0221-7 · Cited by 140 · see citing works
Maxwell, R., Luksik, A. S., Garzón-Muvdi, T., Hung, A. L., Kim, E. S., Wu, A., Xia, Y., Belcaid, Z., Gorelick, N. L., Choi, J. H., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1500108 · Cited by 77 · see citing works
Jessurun, C. A. C., Hulsbergen, A. F. C., de Wit, A. E., Tewarie, I. A., Snijders, T. J., Verhoeff, J. J. C., Phillips, J. G., Reardon, D. A., Mekary, R. A., & Broekman, M. L. D. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab046 · Cited by 67 · see citing works
Immunotherapy failure in adrenocortical cancer: where next?
Cosentini, D., Grisanti, S., Volta, A. D., Laganà, M., Fiorentini, C., Perotti, P., Sigala, S., & Berruti, A. (2018) · Endocrine Connections · doi:10.1530/ec-18-0398 · Cited by 48 · see citing works
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma
Fiorentini, C., Grisanti, S., Cosentini, D., Abate, A., Rossini, E., Berruti, A., & Sigala, S. (2019) · Journal of Oncology · doi:10.1155/2019/6072863 · Cited by 45 · see citing works
Castro, M. A., Corrales, E. P., Molina‐Cerrillo, J., & Alonso‐Gordoa, T. (2021) · Biomedicines · doi:10.3390/biomedicines9030304 · Cited by 43 · see citing works
Ayroldi, E., Cannarile, L., Delfino, D. V., & Riccardi, C. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0558-1 · Cited by 43 · see citing works
Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy
Janowitz, T., Kleeman, S., & Vonderheide, R. H. (2021) · The Oncologist · doi:10.1002/onco.13680 · Cited by 42 · see citing works
Self-citationKleeman, S. O., Thakir, T. M., Demestichas, B., Mourikis, N., Loiero, D., Ferrer, M., Bankier, S., Riazat-Kesh, Y. J. R. A., Lee, H., Chantzichristos, D., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100347 · Cited by 37 · see citing works
Self-citationMarinelli, D., Giusti, R., Mazzotta, M., Filetti, M., Krasniqi, E., Pizzuti, L., Landi, L. M., Tomao, F., Cappuzzo, F., Ciliberto, G., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103176 · Cited by 18 · see citing works
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
Cremaschi, V., Abate, A., Cosentini, D., Grisanti, S., Rossini, E., Laganà, M., Tamburello, M., Turla, A., Sigala, S., & Berruti, A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2106128 · Cited by 21 · see citing works
Flint, T. R., Jones, J. O., Ferrer, M., Colucci, F., & Janowitz, T. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.03.005 · Cited by 19 · see citing works
Self-citationSahara, K., Farooq, S. A., Tsilimigras, D. I., Merath, K., Paredes, A. Z., Wu, L. Y., Mehta, R., Hyer, J. M., Endo, I., & Pawlik, T. M. (2020) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.07.01 · Cited by 18 · see citing works
Trapani, S., Manicone, M., Sikokis, A., D’Abbiero, N., Salaroli, F., Ceccon, G., & Buti, S. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.006 · Cited by 18 · see citing works
Aarnink, A., Fumet, J.-D., Favier, L., Truntzer, C., & Ghiringhelli, F. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03262-2 · Cited by 16 · see citing works
Gobbini, É., Langlais, A., Missy, P., Chanoine, S., Besse, B., Souquet, P.-J., Barlési, F., Audigier-Valette, C., Métivier, A.-C., Monnet, I., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115560 · Cited by 9 · see citing works
Sensitive, non-immunogenic in vivo imaging of cancer metastases and immunotherapy response
Merrill, J. R., Inguscio, A., Chung, T., Demestichas, B. R., Garcia, L. A., Habel, J., Lewis, D. Y., Janowitz, T., & Lyons, S. K. (2023) · Cell Stress · doi:10.15698/cst2023.08.288 · Cited by 8 · see citing works
Self-citationPassiglia, F., Cetoretta, V., Filippis, M. D., Napoli, V. M., & Novello, S. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-635 · Cited by 8 · see citing works
Zhang, Y., Doran, C. R., Le, T. K., Dreyfus, B., Kola, N., Sylvester, B. E., Lal, L. S., Penrod, J. R., & Meadows-Shropshire, S. (2022) · Future Oncology · doi:10.2217/fon-2022-1117 · Cited by 6 · see citing works
Evolving landscape and academic attitudes toward the controversies of global immuno‐oncology trials
Xu, C., Zhang, S., Zhang, Y., Tang, S., Fang, X., Zhu, G., Peng, L., Liu, J.-Q., Mao, Y., Tang, L., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33503 · Cited by 6 · see citing works
Kleeman, S. O., Demestichas, B. R., Mourikis, N., Loiero, D., Ferrer, M., Bankier, S., Riazat‐Kesh, Y. J. R. A., Lee, H., Chantzichristos, D., Regan, C., et al. (2021) · medRxiv · doi:10.1101/2021.08.17.21261668 · Cited by 6 · see citing works
Self-citationEldani, C., Darrigade, A. S., Beylot-Barry, M., Jullié, M., Ducharme, O., Milpied, B., & Pham‐Ledard, A. (2022) · European Journal of Dermatology · doi:10.1684/ejd.2022.4378 · Cited by 5 · see citing works
Awan, S. A., Bharucha, P., Steventon, L., Simpson, H., Ahmad, T., Benafif, S., Shaw, H. M., & Chambers, P. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231207271 · Cited by 4 · see citing works
Cancer Immunotherapy Trials Underutilize Immune Response Monitoring
Connell, C. M., Raby, S., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D. I., & Janowitz, T. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0226 · Cited by 4 · see citing works
Self-citationStrelnikov, J. I., Zhou, A. Y., Butt, O. H., Ansstas, M., & Ansstas, G. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7032 · Cited by 2 · see citing works
Intra-articular Injections for Musculoskeletal Pain in a Cancer Rehabilitation Clinic
Leite, V. F., & Padro‐Guzman, J. (2020) · The Journal of the International Society of Physical and Rehabilitation Medicine · doi:10.4103/jisprm.jisprm_15_20 · Cited by 1 · see citing works
Yu, L. D., Li, Y., Li, C., Qi, X., Lin, Y., Li, Y., Chen, H., & Lin, L. (2024) · Medicine · doi:10.1097/md.0000000000041036 · Cited by 1 · see citing works
Gobbini, É., Langlais, A., Missy, P., Chanoine, S., Besse, B., Souquet, P.-J., Barlési, F., Audigier-Valette, C., Métivier, A.-C., Monnet, I., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5194977 · Cited by 1 · see citing works
Disparities in positive results and dissemination of randomized controlled trials in immuno-oncology
Xu, C., Zhang, S., Zhu, G., Yang, K., Zhang, Y., Mao, Y., Tang, L., Liu, Q., Huang, Y., & Ma, J. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2088744
- Authors
- Connell, C. M., Raby, S., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D. I., & Janowitz, T.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Janowitz, T.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 28
- Issue
- 7
- Pages
- 1678-1679
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC5834107
- OpenAlex
- W2606331198
- Cited by
- 32
- References
- 7
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 4 · 2022: 4 · 2021: 6 · 2020: 6 · 2019: 3 · 2018: 4 · 2017: 2
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Cancer Research UK
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, clinical trial registration, glucocorticoid therapy, immunosuppression, PD-1, CTLA-4, PD-L1, trial exclusion criteria, inclusion and exclusion criteria, solid tumors
- MeSH terms
- Clinical Trials as Topic, Glucocorticoids, Humans, Immunosuppressive Agents, Immunotherapy, Neoplasms, Registries, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
